VTX3232 + Semaglutide for Obesity
Trial Summary
Will I have to stop taking my current medications?
The trial requires that you stop taking certain medications before participating. You must not use any weight loss medications, supplements, or over-the-counter products within 6 months before or during the study, unless they are part of the study treatment. Additionally, you must stop using immunosuppressive biologics, anti-inflammatory medications, colchicine, and glucose-lowering agents for specific periods before starting the trial.
What data supports the effectiveness of the drug Semaglutide for obesity?
Is the combination of VTX3232 and Semaglutide safe for treating obesity?
What makes the drug VTX3232 + Semaglutide unique for treating obesity?
The combination of VTX3232 with semaglutide is unique because semaglutide, a glucagon-like peptide-1 receptor agonist, has shown significant weight loss results, reducing initial weight by about 15% over 68 weeks, and improving cardiovascular risk factors. This combination may offer enhanced benefits compared to semaglutide alone, although specific details about VTX3232's role are not provided.1231011
What is the purpose of this trial?
This is a study to understand if taking VTX3232 alone or in combination with semaglutide is safe in participants diagnosed with Obesity. Approximately 160 patients will take VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide.This study consists of a 30-day Screening Period (to see if a participant qualifies for a study), a 12-week double-blind treatment period (a participant receives VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide), and a 30-day Follow-Up Period. The maximum duration of treatment will be approximately 12 weeks.
Research Team
Snehal Naik, PhD
Principal Investigator
Zomagen Biosciences Ltd.
Eligibility Criteria
This trial is for individuals with obesity who qualify after a 30-day screening. Participants will be randomly assigned to receive either VTX3232 alone, a placebo, VTX3232 with semaglutide, or placebo with semaglutide over a 12-week period followed by a 30-day follow-up.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Semaglutide
- VTX3232
Find a Clinic Near You
Who Is Running the Clinical Trial?
Zomagen Biosciences Ltd.
Lead Sponsor